Literature DB >> 25858663

Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons.

Kara W Chew1, Debika Bhattacharya1, Kathleen A McGinnis2, Tamara B Horwich1, Chi-Hong Tseng1, Judith S Currier1, Adeel A Butt2,3,4,5.   

Abstract

We compared the Framingham risk score (FRS) for 10-year coronary heart disease (CHD) risk in age- and race-matched hepatitis C virus (HCV)-infected and HCV-uninfected persons: 114,073 HCV-infected (111,436 HCV-monoinfected and 2,637 HIV/HCV-coinfected) and 122,996 HCV-uninfected (121,380 HIV and HCV-uninfected and 1,616 HIV-monoinfected) males without cardiovascular disease, diabetes, or hepatitis B. In unadjusted analyses, FRS was similar between the HCV-infected and HCV-uninfected groups [median (interquartile range, IQR) risk points 13 (10-14) vs. 13 (10-14), p=0.192]. Cholesterol levels were lower and current smoking more prevalent in the HCV groups (both HCV and HIV/HCV) compared with the uninfected groups (p<0.001 for both). Prevalence of non-FRS CHD risk factors, such as substance abuse and chronic kidney disease, in the cohort was high, and differed by HCV and HIV status. Adjusting for age, race/ethnicity, body mass index, chronic kidney disease, drug and alcohol use, and HIV status, HCV infection was associated with minimally lower FRS (β=-0.095 risk points, p<0.001), suggesting a small but significant difference in 10-year CHD risk estimation in HCV-infected as compared to HCV-uninfected persons when measuring risk by FRS. Given the complex relationship between HCV, HIV, and CHD risk factors, some of which are not captured by the FRS, the FRS may underestimate CHD risk in HCV-monoinfected and HIV/HCV-coinfected persons. HCV- and HIV/HCV-specific risk scores may be needed to optimize CHD risk stratification.

Entities:  

Mesh:

Year:  2015        PMID: 25858663      PMCID: PMC4505770          DOI: 10.1089/AID.2014.0284

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  38 in total

1.  The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.

Authors:  M G Law; N Friis-Møller; W M El-Sadr; R Weber; P Reiss; A D'Arminio Monforte; R Thiébaut; L Morfeldt; S De Wit; C Pradier; G Calvo; O Kirk; C A Sabin; A N Phillips; J D Lundgren
Journal:  HIV Med       Date:  2006-05       Impact factor: 3.180

2.  Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects.

Authors:  A A Butt; A C Justice; M Skanderson; C Good; C K Kwoh
Journal:  Aliment Pharmacol Ther       Date:  2006-08-15       Impact factor: 8.171

3.  Rate and predictors of treatment prescription for hepatitis C.

Authors:  Adeel A Butt; Amy C Justice; Melissa Skanderson; Michael O Rigsby; Chester B Good; C Kent Kwoh
Journal:  Gut       Date:  2006-09-27       Impact factor: 23.059

4.  Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system.

Authors:  Omer Alyan; Fehmi Kacmaz; Ozcan Ozdemir; Bulent Deveci; Ramazan Astan; Aksuyek Savas Celebi; Erdogan Ilkay
Journal:  Circ J       Date:  2008-10-29       Impact factor: 2.993

Review 5.  Insulin resistance and steatosis in chronic hepatitis C.

Authors:  Mariana V Machado; Helena Cortez-Pinto
Journal:  Ann Hepatol       Date:  2009       Impact factor: 2.400

6.  Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people.

Authors:  P M Polgreen; S L Fultz; A C Justice; J H Wagner; D J Diekema; L Rabeneck; S Weissman; J T Stapleton
Journal:  HIV Med       Date:  2004-05       Impact factor: 3.180

7.  Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans.

Authors:  A A Butt; U A Khan; K A McGinnis; M Skanderson; C Kent Kwoh
Journal:  J Viral Hepat       Date:  2007-12       Impact factor: 3.728

8.  CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus.

Authors:  Andrea Kovacs; Lena Al-Harthi; Shawna Christensen; Wendy Mack; Mardge Cohen; Alan Landay
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

9.  Comparison of two VA laboratory data repositories indicates that missing data vary despite originating from the same source.

Authors:  Kathleen A McGinnis; Melissa Skanderson; Forrest L Levin; Cynthia Brandt; Joseph Erdos; Amy C Justice
Journal:  Med Care       Date:  2009-01       Impact factor: 2.983

10.  Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men.

Authors:  Michelle Floris-Moore; Andrea A Howard; Yungtai Lo; Ellie E Schoenbaum; Julia H Arnsten; Robert S Klein
Journal:  AIDS Patient Care STDS       Date:  2007-07       Impact factor: 5.078

View more
  18 in total

1.  Cigarette Smoking in Persons Living with Hepatitis C: The National Health and Nutrition Examination Survey (NHANES), 1999-2014.

Authors:  Ryung S Kim; Andrea H Weinberger; Geetanjali Chander; Mark S Sulkowski; Brianna Norton; Jonathan Shuter
Journal:  Am J Med       Date:  2018-01-31       Impact factor: 4.965

2.  Hepatitis C Virus Cure and Obesity: Watch the Weight.

Authors:  Nizar A Mukhtar; Rena K Fox
Journal:  J Gen Intern Med       Date:  2020-10       Impact factor: 5.128

3.  Prospective Longitudinal Substance Use Patterns in Patients Preparing for Hepatitis C Treatment.

Authors:  Carol S North; David E Pollio; Omar T Sims; Mamta K Jain; Barry A Hong
Journal:  J Dual Diagn       Date:  2018-01-18

Review 4.  Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

Authors:  R Martin-Iguacel; J M Llibre; N Friis-Moller
Journal:  Curr HIV/AIDS Rep       Date:  2015-12       Impact factor: 5.071

Review 5.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

6.  HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study).

Authors:  Tangui Barré; Patrick Mercié; Fabienne Marcellin; Laure Esterle; Claudine Duvivier; Elina Teicher; Morgane Bureau; Julie Chas; Dominique Salmon-Céron; Philippe Sogni; Maria Patrizia Carrieri; Linda Wittkop; Camelia Protopopescu
Journal:  AIDS Behav       Date:  2021-04-27

Review 7.  Extrahepatic manifestations of hepatitis C infection: navigating CHASM.

Authors:  Amy C Sherman; Kenneth E Sherman
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

Review 8.  HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers.

Authors:  Kaku So-Armah; Matthew S Freiberg
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

9.  Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.

Authors:  Kerry Townsend; Eric G Meissner; Sreetha Sidharthan; Maureen Sampson; Alan T Remaley; Lydia Tang; Anita Kohli; Anu Osinusi; Henry Masur; Shyam Kottilil
Journal:  AIDS Res Hum Retroviruses       Date:  2015-12-15       Impact factor: 2.205

10.  Risk of Acute Myocardial Infarction Among Hepatitis C Virus (HCV)-Positive and HCV-Negative Men at Various Lipid Levels: Results From ERCHIVES.

Authors:  Adeel A Butt; Peng Yan; Kara W Chew; Judith Currier; Kathleen Corey; Raymond T Chung; Ashfaq Shuaib; Abdul-Badi Abou-Samra; Javed Butler; Matthew S Freiberg
Journal:  Clin Infect Dis       Date:  2017-08-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.